دورية أكاديمية
Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study
| العنوان: | Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study |
|---|---|
| المؤلفون: | Sahir Javed, Stéphane Benoist, Patrick Devos, Stéphanie Truant, Rosine Guimbaud, Astrid Lièvre, David Sefrioui, Romain Cohen, Pascal Artru, Aurélien Dupré, Jean-Baptiste Bachet, Christelle de la Fouchardière, Anne Ploquin, Anthony Turpin |
| المصدر: | World Journal of Surgical Oncology, Vol 20, Iss 1, Pp 1-10 (2022) |
| بيانات النشر: | BMC, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Surgery LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Colorectal cancer, BRAF mutation, Drug therapy, Liver metastasis surgery, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Abstract Background BRAF V600E-mutant colorectal cancers (CRCs) are associated with shorter survival than BRAF wild-type tumors. Therapeutic decision-making for colorectal liver metastases (CRLM) harboring this mutation remains difficult due to the scarce literature. The aim was to study a large cohort of BRAF V600E-mutant CRLM patients in order to see if surgery extend overall survival among others prognostic factors. Methods BRAF V600E-mutant CRCs diagnosed with liver-only metastases, resected or not, were retrospectively identified between April 2008 and December 2017, in 25 French centers. Clinical, molecular, pathological characteristics and treatment features were collected. Overall survival (OS) was defined as the time from CRLM diagnosis to death from any cause. Cox proportional hazard models were used for statistical analysis. Results Among the 105 patients included, 79 (75%) received chemotherapy, 18 (17%) underwent upfront CRLM surgery, and 8 (8%) received exclusive best supportive care. CRLM surgery was performed in 49 (46.7%) patients. CRLM were mainly synchronous (90%) with bilobar presentation (61%). The median OS was 34 months (range, 28.9–67.3 months) for resected patients and 10.6 (6.7–12.5) months for unresected patients (P < 0.0001). In multivariate analysis, primary tumor surgery (hazard ratio (HR) = 0.349; 95% confidence interval (CI) 0.164–0.744, P = 0.0064) and CRLM resection (HR = 0.169; 95% CI 0.082–0.348, P < 0.0001) were associated with significantly better OS. Conclusions In the era of systemic cytotoxic chemotherapies, liver surgery seems to extend OS in BRAF V600E-mutant CRCs with liver only metastases historical cohort. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1477-7819 |
| Relation: | https://doaj.org/toc/1477-7819 |
| DOI: | 10.1186/s12957-022-02594-2 |
| URL الوصول: | https://doaj.org/article/396f97762c6d4546b3a537ee0d4435cb |
| رقم الأكسشن: | edsdoj.396f97762c6d4546b3a537ee0d4435cb |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 14777819 |
|---|---|
| DOI: | 10.1186/s12957-022-02594-2 |